About Yposkesi
Yposkesi is a Healthcare company based in Paris (France) founded in 2016, and was acquired by SK in March 2021. Gene and cell therapy products, including lentiviral vectors, are manufactured. Its chief executive, as recorded, is Alain Lamproye. Yposkesi offers products and services including Process Development, Viral Vector Manufacturing, Plasmid DNA Manufacturing, and Cell Therapy Manufacturing. Its focus areas include Biopharma Outsourcing and CDMO. Its legal entity is SK pharmteco Inc.
Company details
Yposkesi was founded in 2016 in Paris, France, as a biotechnology firm focused on gene and cell therapy. Lentiviral and adenoviral vectors, along with CD34 cells for ex vivo applications, are produced. Contract manufacturing services are also provided to support related therapeutic developments in the sector. Operations emphasize advanced vector technologies for clinical and research needs.
- Headquarters Paris, France
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website yposkesi.com
- Social LinkedIn X YouTube
- Acquired by SK (Mar 2021)
- Legal Name Sk Pharmteco Inc.
Products & Services of Yposkesi
Yposkesi offers a comprehensive portfolio of products and services, including Process Development, Viral Vector Manufacturing, Plasmid DNA Manufacturing, and Cell Therapy Manufacturing.
Efficient development for cell and gene therapy processes.
Scalable production of viral vectors for gene therapies.
Production of plasmid DNA for therapy development.
CGMP manufacturing for autologous and allogeneic therapies.
Apps and channels of Yposkesi
its YouTube channel SK pharmteco has 8 subscribers.
Investors in Yposkesi
Yposkesi has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include SK.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on energy, chemical, semiconductor, logistics, and multiple sectors | 1953 | sk.com | Seoul, South Korea |
Investor details for Yposkesi
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Yposkesi
1 people are tracked at Yposkesi (1 in leadership).
| Name | Role | Group |
|---|---|---|
Alain Lamproye | CEO | Leadership |
Complete people profiles for Yposkesi
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Yposkesi
2 dated milestones of Yposkesi across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Yposkesi is founded.
- Exit Acquired by SK.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Yposkesi
Complete news archive for Yposkesi
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Yposkesi
Yposkesi was founded in 2016.
Yposkesi is headquartered in Paris, France.
Alain Lamproye is the CEO of Yposkesi, as recorded in our data.
Yposkesi was founded in 2016 in Paris, France, as a biotechnology firm focused on gene and cell therapy. Lentiviral and adenoviral vectors, along with CD34 cells for ex vivo applications, are produced. Contract manufacturing services are also provided to support related therapeutic developments in the sector. Operations emphasize advanced vector technologies for clinical and research needs.
Yposkesi offers Process Development, Viral Vector Manufacturing, Plasmid DNA Manufacturing, and Cell Therapy Manufacturing.
Yposkesi has 1 investor. Key investors include SK.
Yposkesi operates through Sk Pharmteco Inc..
Yes. Yposkesi was acquired by SK in March 2021.